New biologics in psoriasis: An update on IL-23 and IL-17 Inhibitors

Cutis

Volumn 99, Issue 2, 2017, Pages 123-127

  Dong, Joanna ^a   Goldenberg, Gary ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT; INTERLEUKIN 17; INTERLEUKIN 23; MONOCLONAL ANTIBODY;

ANTAGONISTS AND INHIBITORS; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOLOGY; PSORIASIS; UNITED STATES;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; DRUG APPROVAL; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; PSORIASIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85014856110     PISSN: 00114162     EISSN: 23266929     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496-509.
2. Papp K, Menter A, Sofen H, et al. Efficacy and safety of different dose regimens of a selective IL-23p19 inhibitor (BI 655066) compared with ustekinumab in patients with moderate-to-severe plaque psoriasis with and without psoriatic arthritis. Paper presented at: 2015 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; November 6-11, 2015; San Francisco, CA.
3. New phase 3 data show significant efficacy versus placebo and superiority of guselkumab versus Humira in treatment of moderate to severe plaque psoriasis [press release]. Vienna, Austria; Janssen Research & Development, LLC: October 1, 2016.
4. Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373:136-144.
5. Sun Pharma to announce late-breaking results for investigational IL-23p19 inhibitor, Tildrakizumab, achieves primary end point in both phase-3 studies in patients with moderate-to-severe plaque psoriasis [press release]. Mumbai, India; Sun Pharmaceutical Industries Ltd: October 1, 2016.
6. Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173:930-939.
7. Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345-356.
8. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541-551.
9. Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis [published online June 23, 2016]. Br J Dermatol. 2016;175:273-286.
10. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318-1328.
11. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial [published online March 1, 2015]. J Allergy Clin Immunol. 2015;136:116-124.e7.
12. Chiricozzi A, Romanelli M, Saraceno R, et al. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents [published online August 31, 2016]. Expert Opin Drug Saf. 2016;15:1653-1659.
13. FDA advisory committee recommends approval of brodalumab for treatment of moderate-to-severe plaque psoriasis [news release]. Laval, Quebec: Valeant Pharmaceuticals International, Inc; July 19, 2016.